Showing 161 - 180 results of 25,086 for search '(( 50 ((teer decrease) OR (a decrease)) ) OR ( 5 ((non decrease) OR (nn decrease)) ))', query time: 0.66s Refine Results
  1. 161

    Non-Steady-State Fickian Diffusion Models Decrease the Estimated Gel Layer Diffusion Coefficient Uncertainty for Diffusive Gradients in Thin-Films Passive Samplers by Samuel D. Hodges (16412358)

    Published 2023
    “…A finite difference model (FDM) developed based on Fick’s second law with non-steady-state (N-SS) flux decreased uncertainty in <i>D</i><sub>Gel</sub> tenfold. …”
  2. 162
  3. 163

    Predicting pattern diversity decreases as a function of and . by Selim Haj Ali (21222613)

    Published 2025
    “…(a) and (b): Average negative predictive value for and , respectively for and . …”
  4. 164
  5. 165

    DataSheet_1_Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2.pdf by Yun Ji (464484)

    Published 2022
    “…Here we describe two fully human mAbs, amubarvimab (BRII-196) and romlusevimab (BRII-198) that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein and effectively neutralize SARS-CoV-2 variants. …”
  6. 166
  7. 167
  8. 168
  9. 169
  10. 170
  11. 171
  12. 172
  13. 173

    Image 5_Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture in mi... by Vaskar Das (21529538)

    Published 2025
    “…EC<sub>50</sub> estimates for (2R,6R)-Hydroxynorketamine were 14.2 mg/kg (95% CI: 10.3 mg/kg to 19.7 mg/kg) in male and 16.9 mg/kg (95% CI: 12.8 mg/kg to 22.3 mg/kg) in female mice (P < 0.637). (2R,6R)-Hydroxynorketamine plus meloxicam enhanced the analgesic effect on the AUC<sub>0−3d</sub> of meloxicam alone. (2R,6R)-Hydroxynorketamine analgesia was associated with increases in Glutamate receptor A1 & A2, p-Kv2.1, p-CaMKII and reduced BDNF protein ratios in the hippocampus, attenuated c-Fos in the spinal cord, and decreased BDNF at the dorsal root ganglion (DRG).…”
  14. 174
  15. 175
  16. 176

    Table_1_v2_A long waiting time from diagnosis to treatment decreases the survival of non-small cell lung cancer patients with stage IA1: A retrospective study.docx by Bin Liu (5899)

    Published 2022
    “…Objective<p>The prognostic effect of delayed treatment on stage IA1 non-small cell lung cancer (NSCLC) patients is still unclear. …”
  17. 177
  18. 178
  19. 179

    Pharmacological Mechanism of the Non-hallucinogenic 5‑HT<sub>2A</sub> Agonist Ariadne and Analogs by Michael J. Cunningham (14267038)

    Published 2022
    “…Ariadne is a non-hallucinogenic analog in the phenylalkylamine chemical class of psychedelics that is closely related to an established synthetic hallucinogen, 2,5-dimethoxy-4-methyl-amphetamine (DOM), differing only by one methylene group in the α-position to the amine. …”
  20. 180

    Pharmacological Mechanism of the Non-hallucinogenic 5‑HT<sub>2A</sub> Agonist Ariadne and Analogs by Michael J. Cunningham (14267038)

    Published 2022
    “…Ariadne is a non-hallucinogenic analog in the phenylalkylamine chemical class of psychedelics that is closely related to an established synthetic hallucinogen, 2,5-dimethoxy-4-methyl-amphetamine (DOM), differing only by one methylene group in the α-position to the amine. …”